Advertisement

Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancer—implications for use in pregnancy

      Abstract

      Background

      Although blue dye is routinely used for lymphatic mapping, it is not used for lymphatic mapping in pregnancy-associated breast cancer, because of concern of fetal risk.

      Methods

      To investigate the safety of blue dye for lymphatic mapping in pregnant women, the pharmacokinetics of methylene blue dye were examined in 10 nonpregnant women, and the results were extrapolated to estimate maximal fetal exposure to the dye.

      Results

      Plasma and urine measurements indicated that the dye quickly distributed from the breast injection site to the circulation, with 32% of the total dose excreted in urine within 48 hours. Combined with existing data on organ distribution of methylene blue, the estimated maximal dose to the fetus is 0.25 mg (5% of the administered dose), likely further reduced by other physiologic factors related to pregnancy.

      Conclusions

      The analysis suggests that methylene blue dye can be used for lymphatic mapping in pregnancy-associated breast cancer with minimal fetal risk.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Woo J.C.
        • Yu T.
        • Hurd T.C.
        Breast cancer in pregnancy: a literature review.
        Arch Surg. 2003; 138: 91-98
        • Gentilini O.
        • Masullo M.
        • Rotmensz N.
        • et al.
        Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.
        Eur J Surg Oncol. 2005; 31: 232-236
        • Keleher A.
        • Wendt III, R.
        • Delpassand E.
        • et al.
        The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid.
        Breast J. 2004; 10: 492-495
        • Cody III, H.S.
        • Fey J.
        • Akhurst T.
        • et al.
        Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures.
        Ann Surg Oncol. 2001; 8: 13-19
        • Derossis A.M.
        • Fey J.
        • Yeung H.
        • et al.
        A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer.
        J Am Coll Surg. 2001; 193: 473-478
        • Goyal A.
        • Newcombe R.G.
        • Mansel R.E.
        Relative value of blue dye and isotope in sentinel node localization for breast cancer in a multicentre trial [abstract].
        Eur J Cancer. 2004; 2: 78-79
        • Simmons R.
        • Thevarajah S.
        • Brennan M.B.
        • et al.
        Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization.
        Ann Surg Oncol. 2003; 10: 242-247
        • Blessing W.D.
        • Stolier A.J.
        • Teng S.C.
        • et al.
        A comparison of methylene blue and lymphazurin in breast cancer sentinel node mapping.
        Am J Surg. 2002; 184: 341-345
      1. Methylene blue (systemic). In: Micromedex? Healthcare Series [intranet database]. Version 5.1. Greenwood Village, CO: Thomson Healthcare.

        • Zakaria S.
        • Hoskin T.L.
        • Degnim A.C.
        Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer.
        Am J Surg. 2008; 196: 228-233
        • Schirmer H.
        • Coulibaly B.
        • Stich A.
        • et al.
        Methylene blue as an antimalarial agent—past and future.
        Redox Rep. 2003; 8: 272-276
        • Brooks M.M.
        Methylene blue as an antidode for cyanide and carbon monoxide poisoning.
        Scientific Monthly. 1936; 43: 585-586
        • Camp N.E.
        Methemoglobinemia.
        J Emerg Nurs. 2007; 33: 172-174
        • Cragan J.D.
        Teratogen update: methylene blue.
        Teratology. 1999; 60: 42-48
        • Porat R.
        • Gilbert S.
        • Magilner D.
        Methylene blue-induced phototoxicity: an unrecognized complication.
        Pediatrics. 1996; 97: 717-721
        • Kirsch I.R.
        • Cohen H.J.
        Heinz body hemolytic anemia from the use of methylene blue in neonates.
        J Pediatr. 1980; 96: 276-278
        • Crooks J.
        Haemolytic jaundice in a neonate after intra-amniotic injection of methylene blue.
        Arch Dis Child. 1982; 57: 872-873
        • McEnerney J.K.
        • McEnerney L.N.
        Unfavorable neonatal outcome after intraamniotic injection of methylene blue.
        Obstet Gynecol. 1983; 61: 35S-37S
        • Spahr R.C.
        • Salsburey D.J.
        • Krissberg A.
        • Prin W.
        Intraamniotic injection of methylene blue leading to methemoglobinemia in one of twins.
        Int J Gynaecol Obstet. 1980; 17: 477-478
        • Peter C.
        • Hongwan D.
        • Küpfer A.
        • Lauterburg B.H.
        Pharmacokinetics and organ distribution of intravenous and oral methylene blue.
        Eur J Clin Pharmacol. 2000; 56: 247-250
        • Rengelshausen J.
        • Burhenne J.
        • Fröhlich M.
        • et al.
        Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria.
        Eur J Clin Pharmacol. 2004; 60: 709-715
        • Gibaldi M.
        • Perrier D.
        Noncompartmental analysis based on statistical moment theory.
        in: Swarbrick J. Pharmacokinetics. Marcel Dekker, New York1982: 409-417
        • Corley R.A.
        • Mast T.J.
        • Carney E.W.
        • et al.
        Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments.
        Crit Rev Toxicol. 2003; 33: 137-211
        • Khera S.Y.
        • Kiluk J.V.
        • Hasson D.M.
        • et al.
        Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping.
        Breast J. 2008; 14: 250-254
        • Gentilini O.
        • Cremonesi M.Trifirò
        • et al.
        Safety of sentinel node biopsy in pregnant patients with breast cancer.
        Ann Oncol. 2004; 15: 1348-1351
        • DiSanto A.R.
        • Wagner J.G.
        Pharmacokinetics of highly ionized drugs.
        J Pharm Sci. 1972; 61: 1086-1090
        • Link E.M.
        • Costa D.C.
        • Lui D.
        • et al.
        Targeting disseminated melanoma with radiolabelled methylene blue: comparative bio-distribution studies in man and animals.
        Acta Oncol. 1996; 35: 331-341
        • Luecke R.H.
        • Wosilait W.D.
        • Pearce B.A.
        • Young J.F.
        A physiologically based pharmacokinetic computer model for human pregnancy.
        Teratology. 1994; 49: 90-103
        • Young J.F.
        • Branham W.S.
        • Sheehan D.M.
        • et al.
        Physiological “constants” for PBPK models for pregnancy.
        J Toxicol Environ Health. 1997; 52: 385-401
        • Bernstein I.M.
        • Ziegler W.
        • Badger G.J.
        Plasma volume expansion in early pregnancy.
        Obstet Gynecol. 2001; 97: 669-672
        • Davison J.M.
        • Lindheimer M.D.
        Volume homeostasis and osmoregulation in human pregnancy.
        Baillieres Clin Endocrinol Metab. 1989; 3: 451-472
        • Conrad K.P.
        Mechanisms of renal vasodilation and hyperfiltration during pregnancy.
        J Soc Gynecol Investig. 2004; 11: 438-448